Imaging Young Myeloma (IMAgerie JEune Myélome)
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Registration Number
- NCT01309334
- Lead Sponsor
- Nantes University Hospital
- Brief Summary
Multicenter open-label prospective comparative study of PET-scan and MRI at the time of diagnosis, after 3 cycles of induction therapy (RVD) and at the completion of therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 152
Inclusion Criteria
- symptomatic de novo multiple myeloma
- less than 65 years of age
- enrolled in the IFM/DFCI clinical trial
Exclusion Criteria
- 66 years of age or more
- not eligible for high-dose therapy
- Cons-indications to MRI or PET-Scan
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Number of patients with at least one lesion not detected on the MRI lesions At diagnosis
- Secondary Outcome Measures
Name Time Method diffuse disease at diagnosis Diagnosis time (inclusion) Direct costs of PET and MRI at diagnosis, after the first cycles of chemotherapy and before the maintenance treatment Inclusion, 3 months and 7 months Negativity of the exam after 3 cycles of chemotherapy and just before the maintenance treatment 3 months and 7 months Number of lesions at diagnosis Inclusion (diagnosis)
Trial Locations
- Locations (17)
Bordeaux University Hospital
🇫🇷Bordeaux, France
Brest University Hospital "CHU du Morvan"
🇫🇷Brest, France
Hospital "Côte de Nacre"
🇫🇷Caen, France
Clermont-Ferrand University Hospital
🇫🇷Clermont-Ferrand, France
Dijon University Hospital
🇫🇷Dijon, France
Grenoble University Hospital "Hôpital Michallon"
🇫🇷Grenoble, France
Le Mans Hospital
🇫🇷Le Mans, France
Lille University Hospital "Claude Huriez"
🇫🇷Lille, France
Lyon University Hospital
🇫🇷Lyon, France
"Institut Paoli Calmettes"
🇫🇷Marseille, France
Scroll for more (7 remaining)Bordeaux University Hospital🇫🇷Bordeaux, France